

Adipocyte Calcium Sensing Receptor is not involved in *in-vivo* visceral adipose tissue inflammation or atherosclerosis development in hyperlipidemic *Apoe*^{-/-} mice.

Sai Sahana Sundararaman¹⁻³, Linsey J.F. Peters¹⁻⁴, Yvonne Jansen⁴, Selin Gencer⁴, Yi Yan^{4,5}, Sumra Nazir¹⁻³, Andrea Bonnin-Marquez¹⁻³, Florian Kahles⁶, Michael Lehrke⁶, Erik A.L. Biessen^{2,3}, Joachim Jankowski^{2,3}, Christian Weber^{4-5,7-8}, Yvonne Döring^{4-5,9}, Emiel P.C. van der Vorst^{1-5,*}

1. Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, Aachen, Germany (DE)
2. Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Aachen, Germany (DE)
3. Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, Netherlands (NL)
4. Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Munich, Germany (DE)
5. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (DE)
6. Department of Internal Medicine I-Cardiology, University Hospital Aachen, Aachen, Germany (DE)
7. Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, Netherlands (NL)
8. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (DE)
9. Department of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Switzerland (CH)

Contact information

Dr. Emiel P.C. van der Vorst

Pauwelsstrasse 30, 52074, Aachen, Germany

E-Mail: evandervorst@ukaachen.de

Tel: 0049-241-80-36914

Abstract

The calcium sensing receptor (CaSR) is a G-protein coupled receptor that especially plays an important role in the sensing of extracellular calcium to maintain its homeostasis. Several *in-vitro* studies demonstrated that CaSR plays a role in adipose tissue metabolism and inflammation. As adipose tissue inflammation results in systemic inflammation and contributes to atherosclerosis development, the aim of this study was to investigate whether adipocyte CaSR plays a role in adipocyte tissue inflammation *in-vivo* and atherosclerosis development.

By using a newly established conditional (mature) adipocyte specific CaSR deficient mouse on a hyperlipidemic and atherosclerosis prone *Apoe*^{-/-} background it could be shown that CaSR deficiency in adipocytes does neither contribute to initiation nor to progression of atherosclerotic plaques as judged by the unchanged lesion size or composition. Additionally, CaSR deficiency did not influence visceral adipose tissue (vAT) inflammation *in-vivo*, although a small decrease in visceral adipose cholesterol content could be observed.

In conclusion, adipocyte CaSR seems not to be involved in vAT inflammation *in-vivo* and does not influence atherosclerosis development in hyperlipidemic *Apoe*^{-/-} mice.

Introduction

Atherosclerosis, a progressive chronic inflammatory disease, is the most common cause of cardiovascular diseases¹. High concentrations of lipids (hyperlipidemia), especially low density lipoprotein (LDL) are one of the main risk factors and contributors to disease progression². Upon stimulation, adipose tissues enlarge and release many different products, like adipokines^{3,4}, chemokines^{5,6}, fatty acids, micro-particles and reactive oxygen species that have a wide range of targets. One of these targets is the cardiovascular system leading to vascular inflammation, accumulation of lipids and atherosclerosis⁷. The adipose tissue secretome is tightly controlled by complex homeostatic control mechanisms⁸. Adipose tissue can become dysfunctional in pathologies like obesity and hypercholesterolemia⁸.

In line with this, the activation of the calcium-sensing receptor (CaSR) elevates, at least *in-vitro*, the expression of pro-inflammatory factors in human adipocytes and adipose tissue in a NF- κ B dependent manner⁹. A self-reinforcing feedback loop exists in which expression of *Casr* increases due to pro-inflammatory cytokines¹⁰. CaSR was discovered a quarter century ago¹¹ and has been shown to play a crucial role in calcium homeostasis in the human body^{12,13}. Not surprisingly, CaSR is therefore also expressed on the cell surfaces of various important organs in the calcium metabolism like parathyroid gland^{14,15}, bone, kidney¹⁶, gut^{17,18} and skin¹⁹. The receptor is a G-protein coupled receptor that is made of 1078 amino acid residues and has 3 structural domains of which the largest domain recognizes calcium ions^{20,21}. The receptor, especially in the parathyroid gland, senses even the smallest changes in circulating calcium ions and uses feedback loops to maintain calcium homeostasis²². Besides maintaining calcium homeostasis, CaSR obviously also plays a role in various other processes, like inflammation²³. Furthermore, it was shown that CaSR activation promotes pre-adipocyte differentiation, adipogenesis and adipocyte differentiation²⁴, while inhibiting lipolysis²⁵. Thus, it is conceivable that CaSR plays a role in both adipocyte tissue inflammation and metabolism, although this remains to be validated in an *in-vivo* setting.

As adipose tissue builds-up and inflammation contributes to systemic inflammation⁸, it is likely that stimulation of these processes by CaSR plays a role in atherosclerosis development. Therefore, we generated (mature) adipocyte specific CaSR deficient mice on an atherosclerosis prone background, to determine whether adipocyte CaSR indeed exacerbates atherosclerosis development by stimulating adipocyte tissue inflammation *in-vivo*.

Results

Adipocyte specific CaSR deficiency does not affect early plaque size or phenotype

To investigate the role of adipocyte CaSR on atherogenesis, *AdipoqCre⁺ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre⁻ Casr^{fllox} Apoe^{-/-}* (control) mice were injected with tamoxifen (to induce Cre expression in mature adipocytes) and fed a high-fat diet (HFD) for 4 weeks (**figure 1a**). Subsequently, atherosclerotic lesion sizes were analysed in the aortic roots and aortic arches (**figure 1b**). No difference was observed in the lesion sizes between *AdipoqCre⁺ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre⁻ Casr^{fllox} Apoe^{-/-}* mice, neither in aortic roots nor arches (**figures 1c and 1d**). Analyses of the lesion composition demonstrated that the relative macrophage content in the plaque did not change in adipocyte CaSR deficient mice, compared to controls (**figure 1e**). Furthermore, collagen content was not changed upon adipocyte CaSR deficiency (**figure 1f**). Systemically, adipocyte CaSR deficiency did not change total plasma triglycerides or cholesterol levels (**figure 1g and 1h**). Flow cytometry analysis of the blood also revealed no changes in circulating leukocyte numbers and profile, platelet counts or body weight (**table 1**).




Figure 1: Adipocyte specific CaSR deficiency does not influence early atherosclerotic lesion development.

a) Representation of the experimental workflow. Mice were crossed and offspring were injected with tamoxifen and fed a HFD for 4 weeks before analysis. **b)** Schematic representation of the areas that were used for analysing atherosclerotic plaques. **c)** Representative images and quantification of aortic root lesions in both *AdipoqCre⁻ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre⁺ Casr^{fllox} Apoe^{-/-}* mice (n=10-12). Scale bar=500μm. **d)** Quantification of aortic arch lesions in *AdipoqCre⁻ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre⁺ Casr^{fllox} Apoe^{-/-}* mice (n=10-15). **e)** Quantification of macrophage content of aortic root lesions in *AdipoqCre⁻ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre⁺ Casr^{fllox} Apoe^{-/-}* mice (n=11-13). **f)** Images to represent the presence of collagen in aortic root lesions and quantification in *AdipoqCre⁻ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre⁺ Casr^{fllox} Apoe^{-/-}* mice (n=11-12). Scale bar=250μm. **g-h)** Quantification of plasma triglycerides (**g**) and cholesterol (**h**) levels of *AdipoqCre⁻ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre⁺ Casr^{fllox} Apoe^{-/-}* mice (n=10-15). Bar graphs are representation of mean ± SEM.

CaSR deficiency in adipocytes does not affect advanced plaque size or phenotype

Although adipocyte CaSR did not influence atherogenesis, it is plausible that potential effects only become evident during later stages of disease development when adipose tissues enlarge and become dysfunctional. Therefore, adipocyte specific CaSR deficient mice and matching controls were fed for 12 weeks with a HFD to investigate the effects on advanced atherosclerotic lesion formation (**figure 2a**). Subsequently, aortic lesions were analysed in the aortic roots, aortic arches and thoraco-

abdominal aorta (**figure 2b**). No differences could be observed in the lesion sizes between *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre- Casr^{fllox} Apoe^{-/-}* mice in either of the investigated vascular locations (**figure 2c-e**). Furthermore, lesion phenotyping in the aortic roots demonstrated that there was no difference in relative macrophage content or collagen content, comparing adipocyte specific CaSR deficient mice with controls (**figure 2f-g**). Plasma total cholesterol and triglycerides levels were also not changed upon adipocyte CaSR deficiency (**figure 2h-i**). There also was no difference in circulating leukocyte numbers and profile, platelet counts or body weight (**table 2**).




Figure 2: Adipocyte specific CaSR deficiency does not influence advanced stages of atherosclerosis.

a) Representation of the experimental workflow. Mice were crossed and offspring were injected with tamoxifen and fed a HFD for 12 weeks before analysis. **b)** Schematic representation of the areas that were used for analysing atherosclerotic plaques. **c)** Representative images and quantification of aortic root lesions in both *AdipoqCre- Casr^{fllox} Apoe^{-/-}* and *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* mice (n=9-10). Scale bar=500µm. **d-e)** Quantification of aortic arch lesions (n=5) (**d**) and thoraco-abdominal aortic lesions (n=9-10) (**e**) in *AdipoqCre- Casr^{fllox} Apoe^{-/-}* and *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* mice. **f)** Quantification of macrophage content of aortic root lesions in *AdipoqCre- Casr^{fllox} Apoe^{-/-}* and *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* mice (n=9). **g)** Images to represent the presence of collagen in plaques in aortic roots and their quantification in *AdipoqCre- Casr^{fllox} Apoe^{-/-}* and *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* mice (n=10). Scale bar=250µm. **h-i)** Quantification of plasma triglycerides (**h**) and cholesterol (**i**) levels of *AdipoqCre- Casr^{fllox} Apoe^{-/-}* and *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* mice (n=10-11). Bar graphs are representation of mean ± SEM.

Deficiency of CaSR in adipocytes does not affect vAT inflammation *in-vivo*

In order to investigate whether adipocyte CaSR influenced vAT inflammation *in-vivo*, vAT harvested from *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* and *AdipoqCre- Casr^{fllox} Apoe^{-/-}* mice after 4 and 12 weeks of HFD was lysed and the inflammatory cytokines, cholesterol and triglycerides were measured in the tissue lysates to observe the local inflammatory response and lipid uptake. Surprisingly, there was no change in the levels of inflammatory cytokines chemokine (C-C motif) ligand 2 (CCL2), Interleukin-6 (IL6) and Tumor Necrosis Factor-α (TNF-α) upon adipocyte CaSR deficiency *in-vivo* (**figure 3a-f**). Furthermore, triglycerides levels in the vAT were not changed (**figure g-h**). Interestingly, the amount of cholesterol in the vAT from *Casr*-deficient mice was reduced after 12 weeks of HFD but not after 4 weeks HFD (**figure 3i-j**).




Figure 3: CaSR in adipocytes does not interfere with vAT inflammation *in-vivo*.

a-f) Inflammatory cytokines CCL2 (**a-b**), IL6 (**c-d**) and TNF-α (**e-f**) were measured in vAT isolated from *AdipoqCre-Casr^{fllox} Apoe^{-/-}* and *AdipoqCre+ Casr^{fllox} Apoe^{-/-}* after 4 (Blue; **a, c, e**; n=10-14) and 12 weeks (Orange; **b, d, f**; n=8-11) of HFD. **g-j)** triglycerides (**g-h**) and cholesterol (**i-j**) in vAT from the mice were measured after 4 (Blue; **g, i**; n=10-15) and 12 weeks (Orange; **h, j**; n=10-11) of HFD. Bar graphs are representation of mean ± SEM. **reflects p<0.01.

Discussion

As several studies have demonstrated that activation of CaSR stimulates adipocyte tissue inflammation *in-vitro*, this study set out to investigate the *in-vivo* effects of adipocyte specific CaSR on inflammation and atherosclerosis development. By using newly established conditional adipocyte-specific CaSR deficient mice on an hyperlipidemic and atherosclerosis prone background, we unexpectedly could not observe any effects of adipocyte CaSR on vAT inflammation *in-vivo* nor in early or advanced atherosclerotic lesion development. Besides lesion size, also lesion composition was unaltered as no difference in macrophage or collagen content could be observed. Additionally, lack of adipocyte CaSR did not influence systemic parameters, like total plasma cholesterol and triglycerides or leukocyte numbers. Strikingly, vAT inflammation was likewise not altered upon *in-vivo* adipocyte specific CaSR deficiency.

Besides maintaining calcium homeostasis, CaSR has been shown to play a role in various other physiological processes. CaSR has been demonstrated to contribute to adipocyte dysfunction *in-vitro* as Cifuentes *et al.* observed that various inflammatory factors, like IL-6, IL-1 β , TNF- α and CCL2, were elevated when CaSR was activated using the calcimimetic Cinacalcet in an adipocyte cell line derived from human liposarcoma (LS14)²⁶. This elevation of inflammatory factors also increased the recruitment of monocytes *in-vitro*, suggesting that CaSR stimulates inflammation. Using a similar approach, it could be shown that besides stimulating inflammation, activation of CaSR in human adipocytes inhibited basal lipolysis *in-vitro*²⁶. Furthermore, CaSR activation elevates pre-adipocyte proliferation²⁷ and CaSR activation in human SW872 adipocytes by GdCl₃ promoted adipocyte differentiation and adipogenesis²⁴, again supporting a role of CaSR in adipose tissue formation and accumulation. Although all the above described studies point towards a potential involvement of CaSR as prominent player in adipose tissue formation and inflammation, *in-vivo* validation was missing so far as all studies were performed *in-vitro* using adipocyte cell lines. Surprisingly, we could not validate the previously observed *in-vitro* effects of CaSR in our *in-vivo* model. Several plausible explanations can be raised to explain this discrepancy. One important difference is the methodology that is used to target the CaSR in the various studies. In our study, we evaluated the effects of long-term ablation of CaSR in mature adipocytes using a genetic approach, while most *in-vitro* studies have used pharmacological CaSR agonists or antagonists. Not only unwanted and yet unidentified side-effects of this pharmacological targeting can occur, but also the time-frame of CaSR targeting is significantly different. Another important aspect that should be noted is the fact that the target cells are quite different in the various experiments. Not only different adipocyte cell-lines from different origins are used, but several studies are also conducted using pre-adipocytes rather than mature adipocytes, while in our study we only targeted mature adipocytes. The importance of this aspect is stressed by the notion that pre-adipocytes can even become phagocytic under specific stimuli and phenocopy macrophages²⁸. Finally, a clear distinction should be made between studies focussing solely on adipocytes and studies like ours focussing on adipose tissue. Adipose tissue does not only consist of adipocytes, but also contains nerve cells, vascular cells, adipocyte progenitor cells, fibroblasts, stem cells and immune cells. Together, these cells release various factors such as inflammatory cytokines or adipokines^{5,29,30}, adiponectin³¹, resistin³², and many complement components^{33,34}. The main cytokines that are produced in adipose tissues are TNF- α and IL6³⁵, which have been demonstrated to play an important role in various vascular pathologies like atherosclerosis³⁶. A study using a co-culture of adipocytes and macrophages *in-vitro* demonstrated that there is a vicious loop present between these two cells mediated by TNF- α and free fatty acids that aggravates inflammatory responses³⁷. Products

released by adipocytes are known to directly target the vessel wall to interfere in the process of atherosclerosis development⁸. This interference is for example caused by endothelial cell activation³⁸, smooth muscle cell proliferation³⁹⁻⁴¹, changing lipid deposition, immune cell attraction and adhesion molecule expression⁴². The fact that adipose tissue is actually a very complex organ and not solely a collection of adipocytes might be another main reason why the deficiency of CaSR specifically in mature adipocytes in our model did not create a difference in the secretome of the vAT nor in systemic effects.

Further supporting the notion that CaSR targeting in adipose tissue should not be restricted to mature adipocytes in order to induce significant effects is the notion that CaSR also plays an important role in immune cells and vascular cells. For example, recent studies have found that CaSR activates the NLRP3 inflammasome in monocytes, thereby driving inflammation and promoting the development of Rheumatoid Arthritis^{43,44}. Additionally, stimulation of CaSR *in-vitro* in monocyte derived macrophages augments the release of inflammatory cytokines, like IL-1 β and TNF- α ⁴⁵. Interestingly, one study even found that Ca²⁺ has an additive effect on chemotaxis of monocytes to CCL2, in a CaSR-dependent manner⁴⁶. All in all, these studies clearly demonstrate that CaSR activation promotes inflammation in immune cells. Additionally, CaSR has been associated with increased cell adhesion and migration, which are crucial steps in atherogenesis⁴⁷. This effect was mediated via interaction of CaSR with integrins, which are cell adhesion molecules that are present on endothelial cells and play an important role in the tight adhesion and migration of immune cells into the vessel wall, further implicating CaSR in (chronic) inflammatory processes like atherosclerosis. The fact that our results demonstrate that adipocyte-specific CaSR deficiency does not influence vAT inflammation and atherosclerosis development, raises the suggestion that CaSR expression on other cells in the vAT, like endothelial cells, monocytes/macrophages and adipose progenitor cells, play a more important role in inflammation than CaSR expression on mature adipocytes. Future studies should thereby focus on the exact role of progenitor, vascular or immune cell expressed CaSR to elucidate the effects of CaSR on adipose tissue inflammation and atherosclerosis development.

Another explanation for the lack of effects of adipocyte CaSR deficiency might be the choice of diet as CaSR has also been clearly associated with obesity⁴⁸. In humans it could be shown that obese subjects presented a high sensitivity for calcium, compared with normal-weight controls, which could be speculated to result from greater activity of CaSR⁴⁹. Furthermore, medium conditioned by adipose tissue explants from obese subjects increased CaSR expression in adipocytes and this CaSR expression was positively associated with BMI from the donor⁵⁰. In addition, there is a positive correlation between CaSR mRNA expression in human vAT and fat percentage⁵¹. Therefore, it is possible that a more extreme condition, like obesity, is needed to distinctively elucidate the role of CaSR on adipose tissue inflammation. These studies will be of major importance as CaSR is currently already being used as therapeutic target in the clinic using calcimimetics like cinacalcet, especially in patients suffering from chronic kidney disease⁵². However, the exact impact of such agents on adipose tissue inflammation and function remains undetermined. Therefore, future studies should also focus on the effects of calcimimetics on adipose tissue inflammation, by treating animals with pharmacological CaSR agonists in different disease conditions like obesity or chronic kidney disease, which could have important clinical implications.

In conclusion, although previous studies demonstrated an important role for CaSR in adipose tissue inflammation *in-vitro* using pharmacological targeting, the conditional (mature) adipocyte specific

CaSR deficiency in hyperlipidemic mice did not appear to have any effects on VAT inflammation *in-vivo* nor on early or late atherosclerosis development in *ApoE*^{-/-} mice. Future studies are needed to elucidate whether CaSR expression on other adipose tissue related cells or in other disease conditions like obesity play a role in adipose tissue inflammation *in-vivo*.

Materials and methods

Mouse lines and atherosclerosis models

The *Casr*-floxed (*Casr^{fl/fl}*) mice, kindly provided by Dr. W. Chang (The University of California San Francisco, USA) were backcrossed with C57Bl/6 *Apoe*^{-/-} mice. For tamoxifen-inducible, adipocyte cell-specific deletion of *Casr*, *Casr^{fl/fl} Apoe*^{-/-} mice were crossed with AdipoqCreER^{T2}-expressing mice ("*AdipoqCre*", Jackson Laboratory, stock No. 025124). To induce *Casr* deletion in mature adipocytes, the mice were injected i.p. with tamoxifen (50 mg/kg body weight, from Sigma-Aldrich and dissolved in Miglyol, Caelo) for 5 consecutive days. Knockout of the *Casr* allele was confirmed using primer-pair combinations detecting the wildtype or floxed allele (5'-GTGACGGAAAACATACTGC-3' and 5'-CGAGTACAGGCTTTGATGC-3') or knockout allele (5'-CCTCGAACATGAACAACTTAATTCGG-3' and 5'-CGAGTACAGGCTTTGATGC-3') (**supplemental figure 1a-b**) and ddPCR (see details below and **supplemental figure 1c**). A recovery period of 1 week after the first tamoxifen injection was allowed after which mice (mixed gender) were fed a high-fat diet (HFD) containing 21% fat and 0.15-0.2% cholesterol (Altromin 132010, Sniff TD88137), starting at 8-10 weeks of age for 4 or 12 weeks. All animal experiments were approved by the local ethical committee (Regierung von Oberbayern, Sachgebiet 54, Germany) and every effort was made to minimize suffering.

Analysis of atherosclerotic lesions using histology and immunofluorescent staining

For analysis of mouse atherosclerotic lesions, the aortic root and thoraco-abdominal aorta were used. In brief, hearts with aortic root were embedded in Tissue-Tek O.C.T. compound (Sakura) for cryo-sectioning. Atherosclerotic lesion size was quantified after HE-staining of 5 µm transverse sections and averages were calculated from 3 sections. The aorta was opened longitudinally, mounted on glass slides and *en face*-stained with Oil-Red-O. Aortic arches with main branch points (brachiocephalic artery, left subclavian artery and left common carotid artery) were fixed with 4% paraformaldehyde and embedded in paraffin. Lesion size was quantified after HE-staining of 3 transverse sections. For analysis of the cellular composition or inflammation of atherosclerotic lesions, sections were stained with an antibody to Mac2 (AbD Serotec). Nuclei were counter-stained by 4',6-Diamidino-2-phenylindol (DAPI). After incubation with a secondary FITC--conjugated antibody (Life Technologies), sections were analyzed using a Leica DMLB fluorescence microscope and charge-coupled device (CCD) camera. Collagen was stained using Masson's Trichrome. Blinded image analysis was performed using Leica Qwin Imaging (Leica Lt.) or Image J software.

Laboratory parameters and flow cytometry

Leukocyte counts in blood were determined using a Celltac Automated Hematology Analyzer (Nihon Kohden) or counting beads (Invitrogen) during flow cytometry analysis. For flow cytometry analysis, whole blood obtained from the retro-orbital plexus of mice was EDTA-buffered and subjected to red blood cell lysis. Leukocyte subsets were analyzed using the following combination of surface markers: neutrophils (CD45⁺CD11b⁺CD115⁻Gr1^{high}), monocytes (CD45⁺CD11b⁺CD115⁺), classical monocytes (Gr1^{high} monocytes), non-classical monocytes (Gr1^{low} monocytes), T-cells (CD45⁺CD3⁺), B-cells (CD45⁺CD19⁺). Cell populations and marker expression were analyzed after appropriate compensation and gating using a FACSCanto-II, FACSDiva software (BD Biosciences) and the FlowJo analysis program (Treestar).

Tissue lysates

Mouse visceral adipose tissue (25 mg) were lysed in 500µl of cell lysis buffer (Cell Signalling Technology, #9803) containing protease inhibitors (Complete Protease Inhibitor Cocktail, Roche) and phosphatase inhibitors (PhosSTOP, Roche) using a TissueLyser (Qiagen) for tissue disruption and homogenization. Protein concentrations were determined using the DC Protein Assay (BioRad).

RNA Isolation

Total RNA isolation was performed by commercially available RNA isolation kit from Qiagen according to the manufacturer's protocol. RNeasy miniprep kit was used for RNA isolation from the adipose tissue. The quality (A_{260}/A_{280}) and the quantity (ng/µL) of the RNA was measured by NanoPhotometer N60/N50 (Implen). A ratio of ~2 for A_{260}/A_{280} was accepted as good quality RNA.

cDNA Synthesis

RNA samples were diluted to the same concentration and the cDNA synthesis was performed via the commercially available iScript cDNA synthesis kit from Bio-Rad according to the manufacturer's protocol.

Droplet Digital PCR

PCR was performed on QX200 Droplet Digital PCR (ddPCR™) system from Bio-Rad. 20µL reaction mixes were prepared using 10µL of 2X ddPCR SuperMix for probes (No dUTP) (Bio-Rad), 1µL of 20X FAM labeled primer/probe for the target gene, 1µL of 20X VIC labeled primer/probe for the housekeeping gene, RNase-/DNase-free water and cDNA sample. Taqman primers were purchased from ThermoFisher Scientific. Droplet generation was performed in the QX200 droplet generator (Bio-Rad) by adding 20µL reaction mix and 70µL droplet generation oil for probes (Bio-Rad) onto DG-8 cartridges covered with gaskets (Bio-Rad). 42µL of the droplet solution (containing up to 20,000 droplets) was transferred to the appropriate PCR plate (Bio-Rad) which was then sealed with a pierceable foil using the PCR plate sealer (Bio-Rad). Cycling was performed in the ddPCR cycler with the following conditions: 10 min at 95°C (enzyme activation), 30 seconds at 94°C (denaturation) and 1 min at 60°C (annealing/extension) for 40 cycles, 10 min at 98°C (enzyme deactivation). The PCR plate was then proceeded to the droplet reader (Bio-Rad). Analysis was performed on QuantaSoft software (Bio-Rad).

Plasma and tissue lipid levels

Cholesterol and triglyceride levels were analysed using mouse EDTA-buffered plasma or lysed tissues and quantified using enzymatic assays (c.f.a.s. Cobas, Roche Diagnostics) according to the manufacturer's protocol.

ELISA

Inflammatory cytokines (IL6, TNF- α , CCL2) were measured using enzymatic assays (ThermoFisher Scientific) according to the manufacturer's protocol.

Statistics

All data are expressed as mean \pm SEM. Statistical analysis were performed using GraphPad Prism 8 (GraphPad Software Inc.). After verifying normal distribution via D'Agostino-Pearson omnibus normality test, unpaired Student's t-test with Welch's correction or Mann-Whitney test were used, as appropriate. P-values < 0.05 were considered as being statistically significant.

References

- 1 Falk, E. Pathogenesis of atherosclerosis. *J Am Coll Cardiol* **47**, C7-12, doi:10.1016/j.jacc.2005.09.068 (2006).
- 2 Boren, J. *et al.* Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* **41**, 2313-2330, doi:10.1093/eurheartj/ehz962 (2020).
- 3 Beltowski, J. Adiponectin and resistin--new hormones of white adipose tissue. *Med Sci Monit* **9**, RA55-61 (2003).
- 4 Montague, C. T. *et al.* Depot-related gene expression in human subcutaneous and omental adipocytes. *Diabetes* **47**, 1384-1391, doi:10.2337/diabetes.47.9.1384 (1998).
- 5 Purohit, A. *et al.* Aromatase activity and interleukin-6 production by normal and malignant breast tissues. *J Clin Endocrinol Metab* **80**, 3052-3058, doi:10.1210/jcem.80.10.7559896 (1995).
- 6 Fried, S. K., Bunkin, D. A. & Greenberg, A. S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *J Clin Endocrinol Metab* **83**, 847-850, doi:10.1210/jcem.83.3.4660 (1998).
- 7 Margaritis, M. *et al.* Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. *Circulation* **127**, 2209-2221, doi:10.1161/CIRCULATIONAHA.112.001133 (2013).
- 8 Oikonomou, E. K. & Antoniadou, C. The role of adipose tissue in cardiovascular health and disease. *Nat Rev Cardiol* **16**, 83-99, doi:10.1038/s41569-018-0097-6 (2019).
- 9 Cifuentes, M. *et al.* Calcium sensing receptor activation elevates proinflammatory factor expression in human adipose cells and adipose tissue. *Mol Cell Endocrinol* **361**, 24-30, doi:10.1016/j.mce.2012.03.006 (2012).
- 10 Canaff, L. & Hendy, G. N. Calcium-sensing receptor gene transcription is up-regulated by the proinflammatory cytokine, interleukin-1 β . Role of the NF- κ B PATHWAY and κ B elements. *J Biol Chem* **280**, 14177-14188, doi:10.1074/jbc.M408587200 (2005).
- 11 Brown, E. M. *et al.* Cloning and characterization of an extracellular Ca²⁺-sensing receptor from bovine parathyroid. *Nature* **366**, 575-580, doi:10.1038/366575a0 (1993).
- 12 Garrett, J. E. *et al.* Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. *J Biol Chem* **270**, 12919-12925, doi:10.1074/jbc.270.21.12919 (1995).
- 13 Hendy, G. N., D'Souza-Li, L., Yang, B., Canaff, L. & Cole, D. E. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. *Hum Mutat* **16**, 281-296, doi:10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A (2000).
- 14 Brown, E. M. & MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signaling. *Physiol Rev* **81**, 239-297, doi:10.1152/physrev.2001.81.1.239 (2001).
- 15 Kantham, L. *et al.* The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. *Am J Physiol Endocrinol Metab* **297**, E915-923, doi:10.1152/ajpendo.00315.2009 (2009).
- 16 Riccardi, D. *et al.* Localization of the extracellular Ca²⁺/polyvalent cation-sensing protein in rat kidney. *Am J Physiol* **274**, F611-622, doi:10.1152/ajprenal.1998.274.3.F611 (1998).
- 17 Chattopadhyay, N. *et al.* Identification and localization of extracellular Ca²⁺-sensing receptor in rat intestine. *Am J Physiol* **274**, G122-130, doi:10.1152/ajpgi.1998.274.1.G122 (1998).
- 18 Gama, L., Baxendale-Cox, L. M. & Breitwieser, G. E. Ca²⁺-sensing receptors in intestinal epithelium. *Am J Physiol* **273**, C1168-1175, doi:10.1152/ajpcell.1997.273.4.C1168 (1997).
- 19 Egbuna, O. *et al.* The full-length calcium-sensing receptor dampens the calcemic response to 1 α ,25(OH)₂ vitamin D₃ in vivo independently of parathyroid hormone. *Am J Physiol Renal Physiol* **297**, F720-728, doi:10.1152/ajprenal.00164.2009 (2009).

- 20 Bai, M., Trivedi, S., Kifor, O., Quinn, S. J. & Brown, E. M. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. *Proc Natl Acad Sci U S A* **96**, 2834-2839, doi:10.1073/pnas.96.6.2834 (1999).
- 21 Ray, K., Clapp, P., Goldsmith, P. K. & Spiegel, A. M. Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction. *J Biol Chem* **273**, 34558-34567, doi:10.1074/jbc.273.51.34558 (1998).
- 22 Chavez-Abiega, S. *et al.* Sensing Extracellular Calcium - An Insight into the Structure and Function of the Calcium-Sensing Receptor (CaSR). *Adv Exp Med Biol* **1131**, 1031-1063, doi:10.1007/978-3-030-12457-1_41 (2020).
- 23 Klein, G. L., Castro, S. M. & Garofalo, R. P. The calcium-sensing receptor as a mediator of inflammation. *Semin Cell Dev Biol* **49**, 52-56, doi:10.1016/j.semcdb.2015.08.006 (2016).
- 24 He, Y. H. *et al.* The calcium-sensing receptor promotes adipocyte differentiation and adipogenesis through PPARgamma pathway. *Mol Cell Biochem* **361**, 321-328, doi:10.1007/s11010-011-1118-5 (2012).
- 25 He, Y. *et al.* Involvement of calcium-sensing receptor in inhibition of lipolysis through intracellular cAMP and calcium pathways in human adipocytes. *Biochem Biophys Res Commun* **404**, 393-399, doi:10.1016/j.bbrc.2010.11.129 (2011).
- 26 Cifuentes, M. & Rojas, C. V. Antilipolytic effect of calcium-sensing receptor in human adipocytes. *Mol Cell Biochem* **319**, 17-21, doi:10.1007/s11010-008-9872-8 (2008).
- 27 Rocha, G. *et al.* Preadipocyte proliferation is elevated by calcium sensing receptor activation. *Mol Cell Endocrinol* **412**, 251-256, doi:10.1016/j.mce.2015.05.011 (2015).
- 28 Charriere, G. *et al.* Preadipocyte conversion to macrophage. Evidence of plasticity. *J Biol Chem* **278**, 9850-9855, doi:10.1074/jbc.M210811200 (2003).
- 29 Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science* **259**, 87-91, doi:10.1126/science.7678183 (1993).
- 30 Kern, P. A. *et al.* The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. *J Clin Invest* **95**, 2111-2119, doi:10.1172/JCI117899 (1995).
- 31 Hu, E., Liang, P. & Spiegelman, B. M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem* **271**, 10697-10703, doi:10.1074/jbc.271.18.10697 (1996).
- 32 Steppan, C. M. *et al.* The hormone resistin links obesity to diabetes. *Nature* **409**, 307-312, doi:10.1038/35053000 (2001).
- 33 Cook, K. S. *et al.* Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. *Science* **237**, 402-405, doi:10.1126/science.3299705 (1987).
- 34 Shimomura, I. *et al.* Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. *Nat Med* **2**, 800-803, doi:10.1038/nm0796-800 (1996).
- 35 Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P. & Bahouth, S. W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. *Endocrinology* **145**, 2273-2282, doi:10.1210/en.2003-1336 (2004).
- 36 Ramji, D. P. & Davies, T. S. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. *Cytokine Growth Factor Rev* **26**, 673-685, doi:10.1016/j.cytogfr.2015.04.003 (2015).
- 37 Suganami, T., Nishida, J. & Ogawa, Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α . *Arterioscler Thromb Vasc Biol* **25**, 2062-2068, doi:10.1161/01.ATV.0000183883.72263.13 (2005).
- 38 Verma, S. *et al.* Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. *Circulation* **108**, 736-740, doi:10.1161/01.CIR.0000084503.91330.49 (2003).

- 39 Calabro, P., Samudio, I., Willerson, J. T. & Yeh, E. T. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. *Circulation* **110**, 3335-3340, doi:10.1161/01.CIR.0000147825.97879.E7 (2004).
- 40 Viedt, C. *et al.* Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. *Arterioscler Thromb Vasc Biol* **22**, 914-920, doi:10.1161/01.atv.0000019009.73586.7f (2002).
- 41 Watanabe, T., Pakala, R., Katagiri, T. & Benedict, C. R. Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. *J Vasc Res* **38**, 341-349, doi:10.1159/000051065 (2001).
- 42 Ouchi, N. *et al.* Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation* **100**, 2473-2476, doi:10.1161/01.cir.100.25.2473 (1999).
- 43 Jager, E. *et al.* Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. *Nat Commun* **11**, 4243, doi:10.1038/s41467-020-17749-6 (2020).
- 44 Rossol, M. *et al.* Extracellular Ca²⁺ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. *Nat Commun* **3**, 1329, doi:10.1038/ncomms2339 (2012).
- 45 Xi, Y. H. *et al.* The functional expression of calcium-sensing receptor in the differentiated THP-1 cells. *Mol Cell Biochem* **342**, 233-240, doi:10.1007/s11010-010-0489-3 (2010).
- 46 Olszak, I. T. *et al.* Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo. *J Clin Invest* **105**, 1299-1305, doi:10.1172/JCI9799 (2000).
- 47 Tharmalingam, S. *et al.* Calcium-sensing receptor modulates cell adhesion and migration via integrins. *J Biol Chem* **286**, 40922-40933, doi:10.1074/jbc.M111.265454 (2011).
- 48 Villarroel, P., Villalobos, E., Reyes, M. & Cifuentes, M. Calcium, obesity, and the role of the calcium-sensing receptor. *Nutr Rev* **72**, 627-637, doi:10.1111/nure.12135 (2014).
- 49 Hultin, H., Edfeldt, K., Sundbom, M. & Hellman, P. Left-shifted relation between calcium and parathyroid hormone in obesity. *J Clin Endocrinol Metab* **95**, 3973-3981, doi:10.1210/jc.2009-2822 (2010).
- 50 Cifuentes, M. *et al.* Obesity-associated proinflammatory cytokines increase calcium sensing receptor (CaSR) protein expression in primary human adipocytes and LS14 human adipose cell line. *Arch Biochem Biophys* **500**, 151-156, doi:10.1016/j.abb.2010.05.033 (2010).
- 51 Mattar, P. *et al.* Calcium-Sensing Receptor in Adipose Tissue: Possible Association with Obesity-Related Elevated Autophagy. *Int J Mol Sci* **21**, doi:10.3390/ijms21207617 (2020).
- 52 Evenepoel, P. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. *Kidney Int* **74**, 265-275, doi:10.1038/ki.2008.166 (2008).

Acknowledgements

C.W. is a Van de Laar professor of atherosclerosis.

Author contributions

S.S.S. performed experiments, analysis and wrote the manuscript

L.J.F.P. performed experiments and analysis

Y.J. performed experiments and analysis

S.G. performed experiments and analysis

Y.Y. performed experiments and analysis

S.N. performed experiments and analysis

A.B-M. performed experiments and analysis

F.K. provided crucial material and intellectual support

M.L. provided crucial material and intellectual support

E.B. provided crucial material and intellectual support

J.J. provided crucial material and intellectual support

C.W. provided crucial material and intellectual support

Y.D. provided crucial material and intellectual support

E.P.C.v.d.V performed experiments, analysis and revised the manuscript

Additional Information

The authors declare that they have no competing interests.

The authors' research is supported by the European Research Council AdG°692511 and German Centre for Cardiovascular Research (DZHK;81Z0600202) to C.W; by the Deutsche Forschungsgemeinschaft to JJ (SFB TRR219, C-03) and ML (SFB TRR219, M-03); by the Alexander von Humboldt Foundation, a grant from the Interdisciplinary Center for Clinical Research within the faculty of Medicine at the RWTH Aachen University, the DZHK (German Centre for Cardiovascular Research) and the BMBF (German Ministry of Education and Research), and NWO-ZonMw Veni (91619053) to E.P.C.v.d.V.

Table 1: Body weight and immune cells in blood in mice fed with HFD for 4 weeks

4 Weeks HFD	<i>AdipoqCre-Casr^{flox} Apoe^{-/-}</i> (n=13-15)	<i>AdipoqCre+Casr^{flox} Apoe^{-/-}</i> (n=9-10)	P-value
Leukocytes [x 10 ⁶ /ml]	1.9 ± 0.2	2.4 ± 0.5	0.3789
Neutrophils [x 10 ⁵ /ml]	6.6 ± 0.8	5.6 ± 1.0	0.6850
Classical Monocytes [x 10 ⁵ /ml]	1.7 ± 0.2	1.8 ± 0.6	0.9763
Non-classical Monocytes [x 10 ⁴ /ml]	8.1 ± 1.3	5.6 ± 1.0	0.3268
B cells [x 10 ⁵ /ml]	5.7 ± 0.7	5.2 ± 0.7	0.8776
T cells [x 10 ⁴ /ml]	2.2 ± 0.3	2.4 ± 0.3	0.9327
Thrombocytes [x10 ³ /μl]	588 ± 70	839 ± 92	0.8719
Body weight (g)	26.8 ± 1.0	27.2 ± 1.4	0.8159

Table 2: Body weight and immune cells in blood in mice fed with HFD for 12 weeks

12 Weeks HFD	<i>AdipoqCre-Casr^{flox} Apoe^{-/-}</i> (n=11)	<i>AdipoqCre+Casr^{flox} Apoe^{-/-}</i> (n=9-10)	P-value
Leukocytes [x 10 ⁶ /ml]	1.6 ± 0.5	1.1 ± 0.4	0.5239
Neutrophils [x 10 ⁵ /ml]	9.9 ± 2.6	6.9 ± 1.1	0.3100
Classical Monocytes [x 10 ⁵ /ml]	1.6 ± 0.2	1.2 ± 0.3	0.3920
Non-classical Monocytes [x 10 ⁴ /ml]	8.6 ± 1.5	10.3 ± 3.1	0.6269
B cells [x 10 ⁵ /ml]	1.2 ± 0.2	1.1 ± 0.3	0.7920
T cells [x 10 ⁴ /ml]	5.1 ± 0.9	4.7 ± 1.5	0.8346
Thrombocytes [x10 ³ /μl]	1120 ± 94	1085 ± 135	0.8316
Body weight (g)	21.86 ± 1.0	23.86 ± 1.0	0.264

--	--	--	--